CoChat

Limb‐girdle muscular dystrophy type 2D gene therapy restores α‐sarcoglycan and associated proteins

Open access
Mendell, Jerry R., Rodino‐Klapac, Louise R., Rosales‐Quintero, Xiomara, Kota, Janaiah, Coley, Brian D., Galloway, Gloria, Craenen, Josepha M., Lewis, Sarah, Malik, Vinod, Shilling, Christopher, Byrne, Barry J., Conlon, Thomas, Campbell, Katherine J., Bremer, William G., Viollet, Laurence, Walker, Christopher M., Sahenk, Zarife, Clark, K. Reed · 2009 · Annals of Neurology
Cited by 214

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Objective: α‐Sarcoglycan deficiency results in a severe form of muscular dystrophy (limb‐girdle muscular dystrophy type 2D [LGMD2D]) without treatment. Gene replacement represents a strategy for correcting the underlying defect. Questions related to this approach were addressed in this clinical trial, particularly the need for immunotherapy and persistence of gene expression. Methods: A double‐blind, randomized controlled trial using rAAV1.tMCK.hSGCA injected into the extensor digitorum brevis muscle was conducted. Control sides received saline. A 3‐day course of methylprednisolone accompanied gene transfer without further immune suppression. Results: No adverse events were encountered. SGCA gene expression increased 4–5‐fold over control sides when examined at 6 weeks (2 subjects) and 3 months (1 subject). The full sarcoglycan complex was restored in all subjects, and muscle fiber size was increased in the 3‐month subject. Adeno‐associated virus serotype 1 (AAV1)‐neutralizing antibodies were seen as early as 2 weeks. Neither CD4+ nor CD8+ cells were increased over contralateral sides. Scattered foci of inflammation could be found, but showed features of programmed cell death. Enzyme‐linked immunospot (ELISpot) showed no interferon‐γ response to α‐SG or AAV1 capsid peptide pools, with the exception of a minimal capsid response in 1 subject. Restimulation to detect low‐frequency capsid‐specific T cells by ELISpot assays was negative. Results of the first 3 subjects successfully achieved study aims, precluding the need for additional enrollment. Interpretation: The finding of this gene replacement study in LGMD2D has important implications for muscular dystrophy. Sustained gene expression was seen, but studies over longer time periods without immunotherapy will be required for design of vascular delivery gene therapy trials. Ann Neurol 2009;66:290–297

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.21732

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 214

Metadata

Authors
Mendell, J. R., Rodino‐Klapac, L. R., Rosales‐Quintero, X., Kota, J., Coley, B. D., Galloway, G., Craenen, J. M., Lewis, S., Malik, V., Shilling, C., Byrne, B. J., Conlon, T., Campbell, K. J., Bremer, W. G., Viollet, L., Walker, C. M., Sahenk, Z., & Clark, K. R.
Venue
Annals of Neurology
Publisher
Wiley
Published
2009-09
Volume
66
Issue
3
Pages
290-297
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W1973065533
Cited by
214
References
5
FWCI
11.05
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Limb‐girdle muscular dystrophy type 2D gene therapy restores α‐sarcoglycan and associated proteins. https://app.cochat.ai/papers/10.1002/ana.21732
The paper
Mendell, J. R., Rodino‐Klapac, L. R., Rosales‐Quintero, X., Kota, J., Coley, B. D., Galloway, G., Craenen, J. M., Lewis, S., Malik, V., Shilling, C., Byrne, B. J., Conlon, T., Campbell, K. J., Bremer, W. G., Viollet, L., Walker, C. M., Sahenk, Z., & Clark, K. R. (2009). Limb‐girdle muscular dystrophy type 2D gene therapy restores α‐sarcoglycan and associated proteins. Annals of Neurology. https://doi.org/10.1002/ana.21732

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.